



**TTK Healthcare
LIMITED**

TTKHC:SEC:GJ:030:21

February 04, 2021

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra East
Mumbai 400 051

SCRIP CODE: 507747

SCRIP CODE: TTKHLTCARE

Dear Sirs,

**Re : Unaudited Financial Results along with Limited Review Report for the Third
Quarter ended 31st December, 2020**

We are forwarding herewith the Unaudited Financial Results along with the Limited Review Report from the Statutory Auditors of the Company, for the Third Quarter ended 31st December, 2020, duly reviewed by the Audit Committee at their meeting held yesterday (i.e.) on 3rd February, 2021 and approved by the Board of Directors of the Company at their Meeting held today.

Kindly take the above documents on record.

Thanking you

Yours faithfully
For TTK Healthcare Limited

(S KALYANARAMAN)
Wholetime Director & Secretary

Encl. : a/a



TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND PERIOD ENDED 31ST DECEMBER, 2020

[Prepared in compliance with the Indian Accounting Standards (Ind AS)]

Sl. No.	Particulars	For the Quarter ended			For the period ended		(Rs. in lakhs)
		(31/12/2020)	(30/09/2020)	(31/12/2019)	(31/12/2020)	(31/12/2019)	For the year ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I.	Revenue from Operations	17,918.97	15,966.63	16,580.71	45,525.27	50,925.23	64,576.78
II.	Other Income	253.39	215.29	222.39	661.14	603.24	877.54
III.	Total Income (I + II)	18,172.36	16,181.92	16,803.10	46,186.41	51,528.47	65,454.32
IV.	Expenses						
	(a) Cost of materials consumed	2,701.73	2,669.67	2,595.95	6,978.28	7,813.85	10,413.09
	(b) Purchase of Stock-in-trade	4,379.77	3,588.68	3,882.00	10,149.68	12,973.14	16,971.40
	(c) Changes in inventories of Finished Goods, Work-in-progress and Stock-in-trade	(174.86)	(152.26)	(59.71)	695.45	(263.51)	(1,382.37)
	(d) Employee benefits expense	4,080.74	3,929.87	3,684.96	11,577.72	11,209.26	14,394.10
	(e) Finance Costs	35.29	58.49	90.87	156.59	234.02	326.85
	(f) Depreciation and Amortization Expense	336.74	343.26	365.74	1,033.46	1,078.04	1,437.67
	(g) Other Expenses	5,750.49	5,025.97	5,607.29	14,106.82	16,635.31	21,351.10
	Total Expenses (IV)	17,109.90	15,463.68	16,167.10	44,698.00	49,680.11	63,511.84
V.	Profit / (Loss) before Exceptional Items and Tax (III - IV)	1,062.46	718.24	636.00	1,488.41	1,848.36	1,942.48
VI.	Exceptional Items [Refer Note No.4 below]	-	(809.79)	-	(809.79)	-	-
VII.	Profit / (Loss) before Tax (V - VI)	1,062.46	1,528.03	636.00	2,298.20	1,848.36	1,942.48
VIII.	Tax Expense:						
	(1) Current Tax	340.00	420.00	193.00	760.00	500.00	585.00
	(2) Deferred Tax	(46.20)	(8.03)	(4.76)	(106.30)	158.60	125.54
	(3) Tax relating to earlier years [Refer Note No.4 below]	-	(1,964.81)	-	(1,964.81)	-	-
IX.	Profit / (Loss) for the period from Continuing Operations (VII-VIII)	768.66	3,080.87	447.76	3,609.31	1,189.76	1,231.94
X.	Profit / (Loss) from Discontinued Operations	-	-	-	-	-	-
XI.	Tax Expense of Discontinued Operations	-	-	-	-	-	-
XII.	Profit / (Loss) from Discontinued Operations (after tax) (X - XI)	-	-	-	-	-	-
XIII.	Profit / (Loss) for the period (IX + XII)	768.66	3,080.87	447.76	3,609.31	1,189.76	1,231.94
XIV.	Other Comprehensive Income:						
	(A) (i) Items that will not be reclassified subsequently to profit or loss	16.12	130.59	(90.07)	246.47	(275.58)	(678.28)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.56)	(3.25)	3.99	2.35	(12.76)	54.38
	(B) (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV.	Total Comprehensive Income for the period (XIII + XIV) [Comprising Profit / (Loss) and Other Comprehensive Income for the period]	784.22	3,208.21	361.68	3,858.13	901.42	608.04
	Paid-up Equity Share Capital (Face Value Rs.10 per share)	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03
	Other Equity as per Balance Sheet of previous accounting year (excluding Revaluation Reserve)	-	-	-	-	-	23,044.83
XVI.	Earnings per Equity Share (For Continuing Operations):						
	(1) Basic (in Rs.)	5.44	21.80	3.17	25.54	8.42	8.72
	(2) Diluted (in Rs.)	5.44	21.80	3.17	25.54	8.42	8.72
XVII.	Earnings per Equity Share (For Discontinued Operations):						
	(1) Basic (in Rs.)	-	-	-	-	-	-
	(2) Diluted (in Rs.)	-	-	-	-	-	-

XVIII. Earnings per Equity Share (For Continuing and Discontinued Operations):							
(1)	Basic (in Rs.)	5.44	21.80	3.17	25.54	8.42	8.72
(2)	Diluted (in Rs.)	5.44	21.80	3.17	25.54	8.42	8.72

Notes:

- (1) The above financial results for the Third Quarter and Period ended 31st December, 2020 in respect of TTK Healthcare Limited (the Company) have been reviewed by the Audit Committee at its meeting held on 3rd February, 2021 and approved by the Board of Directors of the Company at its meeting held on 4th February, 2021, through Video Conferencing (VC).
- (2) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (3) The Company has considered the possible impact that may arise from CoVID-19, a global pandemic, on the carrying amount of its assets including Property, Plant and Equipment, Inventory and Receivables. In developing the assumptions relating to the impact of possible future uncertainties in global economic conditions because of this pandemic, the Company as at the date of approval of these financial results has used internal and external sources of information including economic forecasts. The Company based on current estimates expects that the carrying amount of the above assets will be recovered, net of provisions established. The Company has also assessed the impact of this whole situation on its Capital and Financial Resources, Profitability, Liquidity Position, Internal Financial Controls, etc. and is of the view that based on its present assessment, this situation does not materially impact these financial results. The impact assessment does not indicate any adverse impact on the ability of the Company to continue as a going concern. However, the impact assessment of CoVID-19 is a continuing process, given the uncertainties associated with its nature and duration. The Company will continue to monitor any material changes to future economic conditions.
- (4) Exceptional Items: In respect of tax benefits due to adjustment of unabsorbed losses and depreciation of erstwhile TTK Protective Devices Limited and TSL Techno Services Limited which merged with the Company, with effect from 1st April, 2012, (shown as Contingent Asset in earlier years), the Company has received the revised assessment orders during the Quarter ended 30th September, 2020 and the refund received has been accounted in the said Quarter and the Nine month period ended 31st December, 2020, as follows:
 - (a) Rs.809.79 lakhs towards Interest on Tax Refund received has been treated as Exceptional Income; and
 - (b) Balance Refund received (net of certain provisions considered necessary amounting to Rs.999.74 lakhs) of Rs.1,964.81 lakhs has been accounted as Tax Refund relating to earlier years.
- (5) The Code of Social Security, 2020 ('Code') relating to employee benefits, during employment and post-employment, received Presidential assent on 28th September, 2020. The said Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the rules for quantifying the financial impact are yet to be framed. In view of this, the Company will assess and record the financial impact of the Code when it comes into effect.
- (6) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.
- (7) The Statement is also available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).

For TTK HEALTHCARE LIMITED

T T RAGHUNATHAN
Executive Vice Chairman

Place : Chennai
Date : February 04, 2021



TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086
 CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

SEGMENTWISE REVENUE, RESULTS, ASSETS & LIABILITIES FOR THE QUARTER AND PERIOD ENDED 31ST DECEMBER, 2020

(Rs. in lakhs)

Sl. No.	Particulars	For the Quarter ended			For the period ended		For the year ended
		(31/12/2020)	(30/09/2020)	(31/12/2019)	(31/12/2020)	(31/12/2019)	(31/03/2020)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Segment Revenue: (Sales and Other Operating Income)						
(a)	Pharmaceuticals	6,918.08	6,322.51	6,183.63	17,467.27	18,385.41	23,120.51
(b)	Consumer Products	4,966.52	4,378.85	4,539.37	12,976.96	15,006.25	18,133.39
(c)	Medical Devices	650.94	460.15	1,108.47	1,381.64	3,445.76	4,523.13
(d)	Protective Devices	2,908.76	2,135.69	2,614.72	6,508.98	7,545.71	9,974.45
(e)	Foods	2,468.28	2,657.87	2,129.40	7,166.16	6,496.20	8,773.59
(f)	Others	6.39	11.56	5.12	24.26	45.90	51.71
	Total	17,918.97	15,966.63	16,580.71	45,525.27	50,925.23	64,576.78
	Less : Inter Segment Revenue	-	-	-	-	-	-
	Net Sales / Income from Operations	17,918.97	15,966.63	16,580.71	45,525.27	50,925.23	64,576.78
2.	Segment Results: [Profit (+) / Loss (-) before tax and interest from each segment]						
(a)	Pharmaceuticals	945.65	708.59	655.16	1,801.35	1,890.43	2,101.02
(b)	Consumer Products	506.54	594.95	672.65	1,864.42	1,789.81	1,864.06
(c)	Medical Devices	(165.53)	(241.25)	196.15	(685.79)	605.06	700.70
(d)	Protective Devices	(49.25)	(140.05)	(311.19)	(697.03)	(734.87)	(556.14)
(e)	Foods	45.78	69.00	(245.39)	(15.77)	(746.59)	(1,055.47)
(f)	Others	5.81	8.77	4.60	20.01	27.05	31.25
	Total	1,289.00	1,000.01	971.98	2,287.19	2,830.89	3,085.42
	Less : Finance Cost	35.29	58.49	90.87	156.59	234.02	326.85
	Less : Unallocable Expenses (Net of Unallocable Income)	191.25	(586.51)	245.11	(167.60)	748.51	816.09
	Total Profit (+) / Loss (-) before tax	1,062.46	1,528.03	636.00	2,298.20	1,848.36	1,942.48
		As on 31/12/2020	As on 30/09/2020	As on 31/12/2019	As on 31/12/2020	As on 31/12/2019	As on 31/03/2020
3.	Segment Assets						
(a)	Pharmaceuticals	6,428.89	5,967.16	6,164.49	6,428.89	6,164.49	5,811.37
(b)	Consumer Products	2,491.80	3,255.96	3,859.27	2,491.80	3,859.27	3,950.36
(c)	Medical Devices	3,706.71	3,677.35	4,457.36	3,706.71	4,457.36	4,118.46
(d)	Protective Devices	7,183.37	7,657.09	8,214.19	7,183.37	8,214.19	8,173.71
(e)	Foods	8,856.90	8,699.31	8,491.07	8,856.90	8,491.07	8,344.19
(f)	Others	169.14	163.99	145.98	169.14	145.98	150.57
	Total	28,836.81	29,420.86	31,332.36	28,836.81	31,332.36	30,548.66
	Unallocated	22,698.63	21,138.32	16,213.71	22,698.63	16,213.71	18,177.72
	Total Assets	51,535.44	50,559.18	47,546.07	51,535.44	47,546.07	48,726.38
4.	Segment Liabilities						
(a)	Pharmaceuticals	7,101.51	6,634.10	6,162.13	7,101.51	6,162.13	5,524.74
(b)	Consumer Products	5,897.24	5,292.70	4,362.55	5,897.24	4,362.55	5,123.40
(c)	Medical Devices	1,320.08	1,210.31	1,096.49	1,320.08	1,096.49	1,048.28
(d)	Protective Devices	2,046.37	2,057.07	2,290.93	2,046.37	2,290.93	2,160.83
(e)	Foods	1,664.57	1,741.88	1,416.25	1,664.57	1,416.25	1,358.36
(f)	Others	133.45	133.97	134.74	133.45	134.74	135.00
	Total	18,163.22	17,070.03	15,463.09	18,163.22	15,463.09	15,350.61
	Unallocated	5,038.70	5,939.87	5,247.13	5,038.70	5,247.13	8,476.49
	Total Liabilities	23,201.92	23,009.90	20,710.22	23,201.92	20,710.22	23,827.10

Notes:

1. Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) based on review of performance by the Top Management.
2. Details of products included in each of the Segments are as below :
 - ❖ Pharmaceuticals include products for both Human and Veterinary use.
 - ❖ Consumer Products comprise marketing and distribution of Woodward's Gripewater, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Freshners, etc.
 - ❖ Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc.
 - ❖ Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products.
 - ❖ Foods comprise manufacturing and marketing of Food Products.
 - ❖ "Others" include Printing and Publishing of Maps and Atlases.
3. The segment-wise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment.
4. The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED



Place : Chennai
Date : February 04, 2021

T T RAGHUNATHAN
Executive Vice Chairman

**TTK HEALTHCARE LIMITED**

Regd. Office : No.6, Cathedral Road, Chennai 600 086
 CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND PERIOD ENDED 31ST DECEMBER, 2020

Sl. No.	Particulars	(Rs. in lakhs)					
		For the Quarter ended			For the period ended		For the year ended
		(31/12/2020)	(30/09/2020)	(31/12/2019)	(31/12/2020)	(31/12/2019)	(31/03/2020)
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1.	Total income from Operations	17,918.97	15,966.63	16,580.71	45,525.27	50,925.23	64,576.78
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)	1,062.46	718.24	636.00	1,488.41	1,848.36	1,942.48
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary Items) [Refer Note No.6 below]	1,062.46	1,528.03	636.00	2,298.20	1,848.36	1,942.48
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items) [Refer Note No.6 below]	768.66	3,080.87	447.76	3,609.31	1,189.76	1,231.94
5.	Total comprehensive Income for the period [Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax)]	784.22	3,208.21	361.68	3,858.13	901.42	608.04
6.	Equity Share Capital (Face Value of Rs.10/- per share)	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03
7.	Other Equity as per Balance Sheet of previous accounting year (excluding Revaluation Reserve)	-	-	-	-	-	23,044.83
8.	Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)						
(a)	Basic (in Rs.)	5.44	21.80	3.17	25.54	8.42	8.72
(b)	Diluted (in Rs.)	5.44	21.80	3.17	25.54	8.42	8.72

Notes:

- The above is an extract of the detailed Statement of Unaudited Financial Results for the Third Quarter and Period ended 31st December, 2020, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The full financial results for the Third Quarter and period ended 31st December, 2020 are available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).
- These financial results have been reviewed by the Audit Committee at its meeting held on 3rd February, 2021 and approved by the Board of Directors of the Company at its meeting held on 4th February, 2021, through Video Conferencing (VC).
- The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The Company has considered the possible impact that may arise from CoVID-19, a global pandemic, on the carrying amount of its assets including Property, Plant and Equipment, Inventory and Receivables. In developing the assumptions relating to the impact of possible future uncertainties in global economic conditions because of this pandemic, the Company as at the date of approval of these financial results has used internal and external sources of information including economic forecasts. The Company based on current estimates expects that the carrying amount of the above assets will be recovered, net of provisions established. The Company has also assessed the impact of this whole situation on its Capital and Financial Resources, Profitability, Liquidity Position, Internal Financial Controls, etc. and is of the view that based on its present assessment, this situation does not materially impact these financial results. The impact assessment does not indicate any adverse impact on the ability of the Company to continue as a going concern. However, the impact assessment of CoVID-19 is a continuing process, given the uncertainties associated with its nature and duration. The Company will continue to monitor any material changes to future economic conditions.
- Exceptional Items: In respect of tax benefits due to adjustment of unabsorbed losses and depreciation of erstwhile TTK Protective Devices Limited and TSL Techno Services Limited which merged with the Company, with effect from 1st April, 2012, (shown as Contingent Asset in earlier years), the Company has received the revised assessment orders during the Quarter ended 30th September, 2020 and the refund received has been accounted in the said Quarter and the Nine month period ended 31st December, 2020, as follows:
 - Rs.809.79 lakhs towards Interest on Tax Refund received has been treated as Exceptional Income; and
 - Balance Refund received (net of certain provisions considered necessary amounting to Rs.999.74 lakhs) of Rs.1,964.81 lakhs has been accounted as Tax Refund relating to earlier years.
- The Code of Social Security, 2020 ('Code') relating to employee benefits, during employment and post-employment, received Presidential assent on 28th September, 2020. The said Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the rules for quantifying the financial impact are yet to be framed. In view of this, the Company will assess and record the financial impact of the Code when it comes into effect.
- The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED


T T RAGHUNATHAN
 Executive Vice Chairman

Place : Chennai
 Date : February 04, 2021

PKF SRIDHAR & SANTHANAM LLP

Chartered Accountants

Independent Auditor's Review Report on review of Interim financial results

To the Board of Directors of TTK Healthcare Limited

We have reviewed the accompanying Statement of Unaudited financial results ("the Statement") of TTK Healthcare Limited ("the Company") for the quarter and period ended 31st December 2020. The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Listing obligations) which has been initiated by us for identification purposes.

Management's Responsibility

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

Auditor's Responsibility

Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Emphasis of Matter

We draw attention to Note 3 to the financial results, regarding the management's impairment assessment of property, plant and equipment, right of use assets, intangible assets, investments, trade receivables and inventory valuation as at 31st December 2020 being considered as unimpaired /recoverable based on its internal and external sources of information and estimates, and its judgments on implication expected to arise from COVID-19 pandemic. This being an unprecedented event which is difficult to estimate, the actual implications could vary.

Our conclusion is not modified in respect of the above matter.

For **PKF Sridhar & Santhanam LLP**

Chartered Accountants

Firm's Registration No. 003990S/S200018



S. Rajeshwari

Partner

Membership No. 024105



Place: Chennai

Date: 04-02-2021

UDIN No: 21024105AAAAAJ5484